Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05314621 · ClinicalTrials.gov registry record · Phase 4
A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis
A Phase 4 study, sponsored by Andover Research Eye Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 61
- Enrollment target
NCT05314621 is a Phase 4 study that has completed, run by Andover Research Eye Institute. The registered enrollment target is 61 participants.
The verdict
NCT05314621, a Phase 4 study, has completed, sponsored by Andover Research Eye Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 61 participants
- Enrollment target
Study Summary
This is a single-center, randomized, double-masked, parallel study.
Interventions
- DRUG Saline nasal spray
- DRUG Tears Naturale
- DRUG Fluticasone Propionate
- DRUG olopatadine hydrochloride ophthalmic solution 0.7%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2021-12-31 |
| Est. Completion | 2022-07-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05314621
The ClinicalTrials.gov registry entry for NCT05314621 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andover Research Eye Institute, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Saline nasal spray is the first listed.
NCT05314621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05314621 about?
NCT05314621 is a clinical study titled "A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis". This is a single-center, randomized, double-masked, parallel study.
What is the current status of trial NCT05314621?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 61 participants. The study started on 2021-12-31. Estimated completion is 2022-07-24.
What interventions are being tested in trial NCT05314621?
The interventions under investigation include: Saline nasal spray (DRUG), Tears Naturale (DRUG), Fluticasone Propionate (DRUG), olopatadine hydrochloride ophthalmic solution 0.7%) (DRUG).
Who is sponsoring clinical trial NCT05314621?
This trial is sponsored by Andover Research Eye Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.